PMID- 32038501
OWN - NLM
STAT- MEDLINE
DCOM- 20210201
LR  - 20231113
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 11
DP  - 2020
TI  - The Contribution of Chemoattractant GPCRs, Formylpeptide Receptors, to 
      Inflammation and Cancer.
PG  - 17
LID - 10.3389/fendo.2020.00017 [doi]
LID - 17
AB  - A hallmark of inflammatory responses is leukocyte mobilization, which is mediated 
      by pathogen and host released chemotactic factors that activate 
      Gi-protein-coupled seven-transmembrane receptors (GPCRs) on host cell surface. 
      Formylpeptide receptors (FPRs, Fprs in mice) are members of the chemoattractant 
      GPCR family, shown to be critical in myeloid cell trafficking during infection, 
      inflammation, immune responses, and cancer progression. Accumulating evidence 
      demonstrates that both human FPRs and murine Fprs are involved in a number of 
      patho-physiological processes because of their expression on a wide variety of 
      cell types in addition to myeloid cells. The unique capacity of FPRs (Fprs) to 
      interact with numerous structurally unrelated chemotactic ligands enables these 
      receptors to participate in orchestrated disease initiation, progression, and 
      resolution. One murine Fpr member, Fpr2, and its endogenous agonist peptide, 
      Cathelicidin-related antimicrobial peptide (CRAMP), have been demonstrated as key 
      mediators of colon mucosal homeostasis and protection from inflammation and 
      associated tumorigenesis. Recent availability of genetically engineered mouse 
      models greatly expanded the understanding of the role of FPRs (Fprs) in 
      pathophysiology that places these molecules in the list of potential targets for 
      therapeutic intervention of diseases.
CI  - Copyright (c) 2020 Liang, Chen, Gong, Yoshimura, Le, Wang and Wang.
FAU - Liang, Weiwei
AU  - Liang W
AD  - Department of Immunology, School of Basic Medical Sciences, NHC Key Laboratory of 
      Medical Immunology, Peking University, Beijing, China.
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer 
      Institute at Frederick, Frederick, MD, United States.
FAU - Chen, Keqiang
AU  - Chen K
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer 
      Institute at Frederick, Frederick, MD, United States.
FAU - Gong, Wanghua
AU  - Gong W
AD  - Basic Research Program, Leidos Biomedical Research, Inc., Frederick, MD, United 
      States.
FAU - Yoshimura, Teizo
AU  - Yoshimura T
AD  - Department of Pathology and Experimental Medicine, Graduate School of Medicine, 
      Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
FAU - Le, Yingying
AU  - Le Y
AD  - CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute 
      of Nutrition and Health, Chinese Academy of Sciences, Shanghai, China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Immunology, School of Basic Medical Sciences, NHC Key Laboratory of 
      Medical Immunology, Peking University, Beijing, China.
FAU - Wang, Ji Ming
AU  - Wang JM
AD  - Cancer and Inflammation Program, Center for Cancer Research, National Cancer 
      Institute at Frederick, Frederick, MD, United States.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200124
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Chemotactic Factors)
RN  - 0 (Ligands)
RN  - 0 (Receptors, Formyl Peptide)
RN  - 0 (Receptors, G-Protein-Coupled)
MH  - Animals
MH  - Chemotactic Factors/*physiology
MH  - Homeostasis/genetics
MH  - Humans
MH  - Inflammation/*etiology/genetics
MH  - Ligands
MH  - Mice
MH  - Neoplasms/*etiology/genetics
MH  - Receptors, Formyl Peptide/*physiology
MH  - Receptors, G-Protein-Coupled/*physiology
PMC - PMC6993212
OTO - NOTNLM
OT  - FPRs
OT  - cancer
OT  - chemotaxis
OT  - immunity
OT  - infection
OT  - inflammation
OT  - regulation
EDAT- 2020/02/11 06:00
MHDA- 2020/02/11 06:01
PMCR- 2020/01/01
CRDT- 2020/02/11 06:00
PHST- 2019/10/01 00:00 [received]
PHST- 2020/01/09 00:00 [accepted]
PHST- 2020/02/11 06:00 [entrez]
PHST- 2020/02/11 06:00 [pubmed]
PHST- 2020/02/11 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2020.00017 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2020 Jan 24;11:17. doi: 10.3389/fendo.2020.00017. 
      eCollection 2020.